Product Description: DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR[1].
Applications: Cancer-programmed cell death
Formula: C26H35N5O6
Citations: bioRxiv. 2022 Jul 11./bioRxiv. 2024 Jul 26:2024.07.26.605282./Seoul National University. 2024 Feb./Cell. 2022 Nov 10;185(23):4361-4375.e19./Cell. 2023 Jan 19;186(2):413-427.e17.
References: [1]FEBS Lett. 1995 Jan 2;357(1):93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops./[2]Patel JP, et al. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol. 2006 Dec;12(6):492-500./[3]Gold MS, et al. DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro. Neurosci Lett. 1996 Jul 12;212(2):83-6./[4]Desmeules JA, et al. Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain. 1993 Jun;53(3):277-285.
CAS Number: 78123-71-4
Molecular Weight: 513.59
Compound Purity: 99.90
Research Area: Cancer
Solubility: DMSO : 33.33 mg/mL (ultrasonic)/H2O : ≥ 100 mg/mL
Target: Opioid Receptor
Deutsch
English
